All‐cause mortality · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Incidence of T2DM (N) · people at increased risk for developing type 2 diabetes
Summary of findings: pioglitazone monotherapy may leads to lower incidence of T2DM (N) Diagnostic criteria: 3 studies applied the WHO… compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Cardiovascular mortality · people at increased risk for developing type 2 diabetes
It is very uncertain whether summary of findings: pioglitazone monotherapy changes cardiovascular mortality (N) compared with placebo (very low certainty).
1 finding from 1 review
Non‐fatal myocardial infarction/stroke · people at increased risk for developing type 2 diabetes
It is very uncertain whether summary of findings: pioglitazone monotherapy changes non‐fatal myocardial infarction/stroke (N) compared with placebo (very low certainty).
1 finding from 1 review
Health‐related quality of life · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Socioeconomic effects · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people at increased risk for developing type 2 diabetes
It is very uncertain whether summary of findings: pioglitazone monotherapy changes all‐cause mortality (N) compared with no intervention (very low certainty).
1 finding from 1 review
Incidence of T2DM (N) · people at increased risk for developing type 2 diabetes
Summary of findings: pioglitazone monotherapy probably leads to lower incidence of T2DM (N) Diagnostic criteria: 9 studies applied the WHO… compared with no intervention (moderate certainty).
1 finding from 1 review
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
Summary of findings: pioglitazone monotherapy showed no clear difference in serious adverse events (N) compared with no intervention (low certainty).
1 finding from 1 review
Cardiovascular mortality · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐fatal myocardial infarction/stroke · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Socioeconomic effects · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis
1 finding from 1 review
FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events: occurring in at least 10% of cavosonstat treated participants · adults and children with cystic fibrosis
1 finding from 1 review
Time to first pulmonary exacerbation · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Survival · adults and children with cystic fibrosis
1 finding from 1 review